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DNA hydrogel delivery vehicle for light-triggered
and synergistic cancer therapy†
Jaejung Song,a Kyuhyun Im,b Sekyu Hwang,c Jaehyun Hur,d Jutaek Nam,c
G-One Ahn,e Sungwoo Hwang,b Sungjee Kim*a,c and Nokyoung Park*f
A DNA hydrogel is reported as a delivery vehicle for gold nanorods
and doxorubicin. The two photothermal and chemo cancer agents
were co-loaded using electrostatic and DNA binding interactions,
respectively. Light-triggered and highly synergistic combination
cancer therapy was demonstrated in cellular and animal models.
Gold nanostructures of which the surface plasmon resonance
(SPR)1 is tuned at near-infrared (NIR) wavelengths such as
nanorods,2 nanoshells,3 and nanocages,4 have demonstrated
potential for many deep-tissue penetrating biomedical appli-
cations that include photothermal therapy, Raman imaging
and radio-sensitization. Gold nanorods (AuNRs) have been
widely used for photothermal eﬀects because of their relative
simplicity in synthesis, their strong local heating upon NIR
irradiation that cannot be paralleled by conventional organic
dye-based agents, and resistance against photobleaching.5
Typically, many photothermal agents including gold nano-
particles (NPs) can carry a number of small molecules by their
flexible surface functionalities for eﬃcient drug delivery.6
However, most of the AuNR surfaces are covered by surfactants
such as cetyltrimethylammonium bromide (CTAB) which is
essential for NR morphology control but lacks conjugation
capability. As the result, it is diﬃcult to attain a AuNR hybrid
system that integrates conventional anticancer agents in the
proximity of AuNR and permits multimodal thermo-chemo
combination cancer therapy.7 To achieve the maximal synergis-
tic eﬀect by combination therapy, the proximity between the
two agents is crucial.8 In cases where chemo-agents were com-
bined with NPs by physical mixtures7a,b or by loosely bound
conjugates through hydrophobic interactions,7c the weak
binding between the two agents often results in undesired
separation upon therapeutic administrations which can sig-
nificantly hamper the spatially concerted action for synergistic
eﬀects. Herein, we report a novel AuNR-based thermo-chemo
combination therapy platform with a DNA hydrogel (Dgel)
(Scheme 1). Dgels are three-dimensional structures composed
of internally cross-linked DNA monomers with many nano-
scale pores (Scheme 1a).9 Because the DNA backbone is highly
negatively charged, AuNRs which are positively surface-
charged can be stably incorporated into the Dgel pores by
electrostatic attractions. Dgels are also exploited as templates
for small anticancer drug loading. Dgels can be used as deli-
very vehicles for DNA-binding anticancer drugs with strong
Scheme 1 (a) Schematic drawing of Dgel nanoscaﬀold synthesis. The
X-DNAs with one disabled arm (left) are mixed and ligated to produce
nanoscale Dgel (right). (b) Schematic illustration of the DNA gel, gold
nanorod incorporation, and cancer drug loading. External light trigger-
ing induces the drug release by DNA melting, which permits synergistic
thermo-chemo combination cancer therapy.
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binding aﬃnity preventing biodegradation or uncontrolled
release of the payloads.9a Recently, we have reported a Dgel-
AuNP assembly system for synergistic cancer therapy.10 Dgels
can be used as a biocompatible scaﬀold with unique melting
characteristics by thermal denaturation, which can be used
for triggered drug release and/or programmed disassembly
after therapy (Scheme 1b). The Dgel platform with NIR-
responsive AuNRs and DNA-binding anticancer drugs allow
stable NR and drug loadings and ‘on-demand’ type activation
of the therapeutic combination action by external light
triggering.
Positively charged AuNRs (length 35.6 (±2.6) nm, width 20.9
(±9.9) nm) were prepared by following a seedless growth
method described in the literature (see Fig. 1a for the TEM
image).11 Excess free CTAB in the AuNR solution was rigor-
ously removed by centrifugation and decanting. X-shaped DNA
(X-DNA) was designed to have three sticky ends and one dis-
abled end to control the size of Dgel upon ligation (Scheme 1a,
Table 1). The self-confined geometry by the disabled arm pro-
vided control over the crosslinking and thus yielded Dgels
around one hundred nanometers in size. In the case of X-DNA
with all four sticky ends, the enzymatic crosslinking resulted
in bulk Dgels of over tens of microns in size. Freeze dried Dgel
was swelled under AuNR aqueous solution. Then, the mixture
was centrifuged to remove unassembled free Dgels and AuNRs.
AuNR incorporated Dgel (AuNR-Dgel) was prepared by mixing
Dgels with AuNRs in deionized water. When a Dgel sample
prepared by the ligation of 10 nmol X-DNA was co-incubated
with 2.5 pmol AuNR, near complete incorporation was con-
firmed spectrophotometrically by the absence of free AuNR in
the supernatant after centrifugation. The Dgel retained col-
loidal stability after AuNR loading. TEM measurement showed
tens to hundreds of AuNRs densely incorporated into a Dgel
(Fig. 1b). The average hydrodynamic (HD) sizes determined by
dynamic light scattering were 32 (±14) nm for the AuNR, 87
(±6) nm for the Dgel, and 148 (±67) nm for the AuNR-Dgel
(Fig. S1†). The HD size increase for the Dgel upon AuNR
loading suggests partial inclusion of the AuNRs in the Dgel,
which is expected when considering the significant size of the
AuNRs relative to the Dgel. This was supported by the partial
charge compensation of the Dgel upon AuNR incorporation.
The Dgel initially showed a Zeta potential of −46 mV which
reduced (in absolute value) to −27 mV upon the incorporation
of the AuNRs of which the Zeta potential was 34 mV (Fig. S2†).
Fig. 1c shows the absorption profiles of the AuNRs, Dgel, and
AuNR-Dgel. The AuNRs initially show two distinct plasmon
peaks at 515 and 650 nm which correspond to the transverse
and longitudinal modes, respectively. Upon incorporation into
the Dgel, the AuNRs showed broadened and red-shifted
plasmon peaks. The transverse peak showed ∼20 nm red-shift,
whereas the longitudinal peak did not show much shift
although it manifested a noticeable tailing towards longer
wavelengths. It has been reported by others that a side-by-side
assembly of eight AuNRs (which showed a similar aspect ratio
to what we have used in this paper) resulted in a 20 nm trans-
verse peak shift.12 The larger red-shift of the transverse peak
over the longitudinal peak is presumably due to dominant
side-by-side plasmon couplings between the AuNRs inside
the Dgel. The DNA peak at 260 nm remained unchanged after
the AuNR incorporation, suggesting that the AuNR loading
does not severely perturb the DNA stacking backbones in the
Dgel.
The high-density DNA strands of the Dgel was used to co-
load a DNA binding drug. To obtain doxorubicin (Dox) and
AuNR co-loaded Dgel (Dox-AuNR-Dgel), Dox was co-incubated
Fig. 1 TEM images of the AuNRs (a) and AuNR-Dgel (b). (c) Absorption
spectra of AuNRs, Dgel, and AuNR-Dgel. Laser power dependent
absorption spectra (d) and Dox release percentages (e) of the Dox-
AuNR-Dgel upon irradiation for 5 min. (f ) TEM image of Dox-AuNR-Dgel
after laser irradiation at 16 W cm−2 for 5 min.
Table 1 Sequence design for X-DNA building blocka
Strand
End
segment Main body segment
X01 5′-p-ACGTa CGA CCG ATG AAT AGC GGT CAG ATC CGT
ACC TAC TCG-3′
X02 5′-p-ACGT CGA GTA GGT ACG GAT CTG CGT ATT GCG AAC
GAC TCG-3′
X03 5′-p-ACGT CGA GTC GTT CGC AAT ACG GCT GTA CGT
ATG GTC TCG-3′
X04 5′-(GT)20 CGA GAC CAT ACG TAC AGC ACC GCT ATT CAT
CGG TCG-3′
a 5′-p represents the phospholylated 5′ end of oligonucleotide.
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for 1 h with AuNR-Dgel in deionized water and unloaded free
Dox was removed by centrifugation. The amount of loaded Dox
(obtained by subtracting the amount of unloaded Dox from
the co-incubated Dox) and the number of AuNRs in the
AuNR-Dgel sample were obtained by a spectrophotometric
method using extinction coeﬃcients reported elsewhere.13 On
average, 11 000 Dox molecules were loaded per AuNR
(Fig. S3†). Based on an earlier hypothesis that one million
X-DNAs construct a Dgel, each Dox-AuNR-Dgel was co-loaded
with 250 AuNRs and 2.8 million Dox molecules which corres-
ponds to 2.8 Dox molecules being incorporated into each
X-DNA building block.
Dox-AuNR-Dgel is designed for the light-triggered release of
Dox by plasmonic heat shock. To test if Dox could be released
upon photothermally-triggered DNA melting, a 660 nm laser
which matches the major plasmonic peak of the AuNR was
irradiated to the Dox-AuNR-Dgel samples at diﬀerent laser
power densities for 5 min each. As the laser power increased,
the absorption blue-shifted progressively. The longitudinal
peak of the AuNR shifted abruptly above 8 W cm−2, which indi-
cates that the AuNRs generated suﬃcient energy to melt the
Dgel (Fig. 1d).14 This also accords with the drastically
increased Dox release at or above 8 W cm−2 laser power
(Fig. 1e). The amount of Dox released by the light-triggering
was investigated by the supernatant absorption measurements
after centrifugation. A linear increase by the laser power up to
16 W cm−2 followed by a plateau region was observed (Fig. 1e
and Fig. S4†). Eﬃcient Dox release was demonstrated with a
percentage release as high as 85%. The TEM measurements
show fragmentation of the Dgel template and shape transform-
ations of the AuNRs into more spherical particles (Fig. 1f).
Such AuNR shape deformation is known to occur at a local
temperature of above 200 °C,14 which explains well the
eﬃcient DNA melting and subsequent Dox release. Nearby, the
complete release of Doxs from Dgel is expected as the Dgel
turns into single strands above the melting temperature from
the Dox intercalated B-form of the DNA double stranded
helix.15
The successful demonstration of light-triggered release of
heat shock and Dox allowed us to investigate cellular level
combination cancer therapy. B16 F10 cells were incubated
with Dox-AuNR-Dgel which had been prepared by the ligation
of 0.24 nmol X-DNA and subsequent co-loading of 0.06 pmol
AuNR and 0.03 nmol Dox. Control samples of AuNR-Dgel and
Dox only were also prepared using identical concentrations.
Cellular accumulations of AuNRs were monitored over
time using dark-field microscopy. The Dox-AuNR-Dgel and
AuNR-Dgel showed similar accumulations over time as indi-
cated by the increased orange-color scatterings visualizing the
cell morphologies (Fig. 2a). Cell viabilities were also measured
over time by MTT assay. Under no laser light, no significant
cytotoxicity was observed up to 12 h in all cases (Fig. 2b). At
24 h, slight cytotoxicity was observed for the Dox only control.
Light-triggered release of Dox was confirmed by the appear-
ance of Dox red fluorescence as recovered from the quenched
state in the Dox-AuNR-Dgel (Fig. 2c). Quantitative measure-
ments for the fluorescence can be found in Fig. S5.† Since
internalization of the Dox-AuNR-Dgel and Dox release were
confirmed, we further performed thermo-chemo combination
cancer therapy tests. The co-incubation conditions used for
the dark-field microscopy and MTT assays were adopted, and a
660 nm laser was used for illumination. The circles in Fig. 2d
represent the position of the 660 nm laser spots. The spot has
a ∼500 μm radius, as measured using photosensitive paper.
Each sample was illuminated for 5 min using diﬀerent laser
power densities of 12, 16, 20, 24, and 28 W cm−2. Trypan blue
was used to reveal the mortality of cells by blue staining. In
the case of the Dox-AuNR-Dgel, cell mortality appeared at a
laser power of 16 W cm−2 or higher. The circular areas of
damaged cells increased linearly with the irradiation power
density. AuNR-Dgel showed a significantly larger threshold,
showing mortality at 20 W cm−2 or higher. On the other hand,
no noticeable cell mortality was found for the Dox and non-
treated controls. It is noted that the cells outside of the laser
Fig. 2 (a) Dark-ﬁeld microscopy images of B16 F10 cells co-incubated
with AuNR-Dgel, Dox-AuNR-Dgel, or Dox for 1, 6, 12, or 24 h (scale bar:
20 µm). (b) Viabilities of the B16 F10 cells co-incubated with each
sample for 1, 6, 12 or 24 h (*P = 0.019). (c) Fluorescence microscopy
images of B16 F10 cells co-incubated with Dox-AuNR-Dgel or with Dox
and irradiated with no laser (0 W cm−2) or with laser power of 16 W
cm−2 (scale bar: 40 µm). (d) Photothermal destruction of the cells co-
incubated with Dox-AuNR-Dgel, AuNR-Dgel, Dox, or no sample (non-
treated) for 12 h followed by laser irradiation for 5 min at diﬀerent power
densities (scale bar: 100 µm).
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spot also showed no mortality. As the Dox release concurrently
burst with the heat shock, the thermo and chemo eﬀects
boosted each other. This synergistic eﬀect resulted in the
reduction of the laser threshold for the Dox-AuNR-Dgel over
the AuNR-Dgel. Conversely, this combined therapy would
require a smaller amount of Dox than the uncombined case.
The synergistic eﬀect can potentially mitigate the side eﬀect of
patients by reducing the dosage (or laser power).
To quantify the synergistic eﬀect, viabilities were studied
for cells co-incubated with Dox-AuNR-Dgel and separately with
the AuNR-Dgel, Dox only, and non-treated controls for 12 h by
varying the laser irradiation time from 0 (no exposure), 1, 3, 5,
to 10 min at 16 W cm−2 (Fig. 3a). Dox-AuNR-Dgel showed the
most radical change in the viability by the irradiation time,
dropping to 34.2% at 10 min, which was followed by
AuNR-Dgel showing 60.5% viability under the same irradiation
conditions. This almost two-fold viability reduction of the Dox-
AuNR-Dgel over AuNR-Dgel indicates the highly synergistic
eﬀect of the co-loaded Dox. It is noted that the Dox alone only
showed ∼4% decrease in the viability because of the low
dosage level. Synergistic eﬀects were obtained by dividing the
predicted additive viability by the measured viability (Fig. 3b).8
The additive viability was obtained from the expression VAdditive
= VChemo × VThermo, where VAdditive is the predicted viability as a
result of the purely additive interaction between the chemo
and thermo therapies, and VChemo and VThermo are the viabi-
lities after the chemo and thermo therapies alone, respecti-
vely.7a,16 The synergistic factor was ∼1 for all the samples prior
to laser irradiation, which indicates the absence of any syner-
gistic eﬀect. The largest synergistic increase of 70.0% was
observed for the Dox-AuNR-Dgel sample after 10 min laser
irradiation. The synergistic factor is comparable with maximal
values observed for previous combination treatments using
gold nanostructures with Dox.7c,17 The highly synergistic eﬀect
of the Dox-AuNR-Dgel can be explained by (1) the high local
concentration of Dox released from the Dgel scaﬀold by
thermal denaturation and (2) the photothermally enhanced
induction of the cytotoxic eﬀect of Dox, i.e., thermal
chemopotentiation.18
The eﬃcacy of the combination therapy was further demon-
strated in vivo using a mouse model bearing B16
F10 melanoma xenografts. PBS buﬀer, Dox, AuNR-Dgel, or
Dox-AuNR-Dgel were intratumorally injected, and the tumor
growth was monitored with/without laser irradiation. To
monitor the local heating eﬀect, a thermocouple needle was
inserted into the tumor region 10 min post injection, and the
local temperature was measured for 5 min during irradiation
under 660 nm laser (1 W cm−2) and for another 3 min after
the laser was turned oﬀ (Fig. 4a). Both the AuNR-Dgel and
Dox-AuNR-Dgel showed a rapid temperature increase upon
laser irradiation, which was significantly larger than that of
the PBS or Dox control. This temperature increase should be
suﬃcient for tumor ablation19 and thermal enhancement of
Dox cytotoxicity.18,20 When the laser was turned oﬀ, the tumor
quickly cooled down, implying that the heat generation was
localized. After the intratumoral administration, the mice were
laser-irradiated only once for 5 min on day one. The tumor
suppression eﬃcacy was evaluated by recording the relative
tumour volumes every two days for two weeks (Fig. 4b). Dox-
AuNR-Dgel treated mice showed the most eﬀective tumor sup-
pression, which was followed by AuNR-Dgel and Dox. The Dox-
AuNR-Dgel case showed that the relative tumor volume was 3.9
times smaller than the PBS control. It was also 1.8 times and
2.9 times smaller than those of the AuNR-Dgel and Dox,
respectively, which clearly indicates the synergistic eﬀect. The
experiment was repeated by omitting the laser irradiation,
where no significant tumor suppression was observed (Fig. 4c).
The tumors were dissected after the experiments, and showed
well-correlated size patterns with the temporal volume change
(Fig. 4d). The dissected tumors were measured and compared
by weight, which matched well with the volume data on the
last day (Fig. S6†). These results demonstrate light-controlled
Fig. 4 (a) Local temperature of the tumor core during and after laser
irradiation at 10 min after injection of PBS, Dox, AuNR-Dgel, or Dox-
AuNR-Dgel (*P < 0.05 and **P < 0.005 for comparison with Dox and
PBS). Relative tumor volume change over 15 days with (b) or without (c)
laser irradiation (*P < 0.05, **P < 0.005 and ***P < 0.001 are noted
between PBS and Dox-AuNR-Dgel, #P < 0.05 is noted between
AuNR-Dgel and Dox-AuNR-Dgel). (d) Images of dissected tumors after
the experiment with laser irradiation (L) or without (NL) laser irradiation.
Fig. 3 (a) Viabilities of cells co-incubated with each or no sample and
exposed to laser irradiation. (b) Synergistic eﬀects for the Dox-
AuNR-Dgel (**P = 0.0039).
Communication Nanoscale




















































































activation of thermo-chemo combination therapy, which
shows synergistically enhanced eﬃciency over single
treatment.
In summary, to overcome the limited conjugation capability
of AuNRs, we have employed Dgel as a scaﬀold to assemble
AuNRs with Doxs in nanoscale proximity. This platform can be
potentially applied for CT contrast imaging, radiosensitization,
and so forth.
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